89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class
Executive Summary
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.
You may also be interested in...
Who Will Emerge As Best In Class Of The FGF21 Analogs In NASH?
Akero hopes to begin Phase III study of efruxifermin this year, with 89bio working to enter Phase III with pegozafermin in 2024. But just behind them, Boston Pharmaceuticals thinks it has a convenience and immunogenicity edge.
89bio’s FGF21 Analog May Offer Fibrosis Benefit In Cirrhotic NASH Patients
At AASLD, 89bio presented subgroup analysis from its successful Phase IIb NASH study indicating that the drug may meaningfully reduce fibrosis even in the sickest patients, those with cirrhosis.
Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D
After a multi-year lull, NASH R&D has picked up this past year with key data readouts, several programs advancing toward Phase III and Madrigal's resmetirom under FDA review with a March 2024 action. This graphic provides a look at the overall status of NASH drug R&D.